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Abstract: The pharmacokinetics of [ I  'Cltetrabenazine, a high-affin- 
ity radioligand for the monoamine vesicular transporter, were de- 
termined in living human brain using in vivo imaging by positron 
emission tomography (PET). The radiotracer showed high brain 
uptake and rapid washout from all brain regions with relatively 
slower clearance from regions of highest concentrations of mono- 
amine vesicular transporters (striatum), resulting in clear differen- 
tial visualization of these structures at short intervals after injection 
(10-20 min). As the first human PET imaging study of a vesicular 
neurotransmitter transporter, these experiments demonstrate that 
external imaging of vesicular transporters forms a new and valuable 
approach to the in vivo quantification of monoaminergic neurons, 
with potential application to the in vivo study of neurodegenerative 
disorders such as Parkinson's disease. Key Words: Positron emis- 
sion tomography-['1C]Tetrabenazine-Vesicle-Transporter- 
Monoamine-Parkinson's disease-Striatum. Kilbourn M. R. et 
al. In vivo imaging of vesicular monoamine transporters in human 
brain using ["C]tetrabenazine and positron emission tomography. 
J.  Neurochem. 60, 23 15-23 18 (1993). 
The availability of specific radioligands for discrete neuro- 
nal populations, suitable for in vivo imaging of nerve termi- 
nals using positron emission tomography (PET), would be 
of immense value in the study of neurodegenerative dis- 
orders such as Parkinson's or Alzheimer's disease. Re- 
peated. noninvasive, quantitative measures of presynaptic 
nerve terminal densities would be useful in determining the 
rate and extent of neuronal loss during the onset and pro- 
gression of these diseases and provide objective measures of 
therapies intended to prevent or delay further degeneration. 
Previous approaches to dopaminergic nerve terminal imag- 
ing have used 6-['*F]fluoroDOPA (for review, see Leenders, 
199 1 )  or radioligands that bind to the neuronal membrane 
dopamine (DA) transporters (for review, see Salmon, 1991). 
The neurochemical basis for cerebral localization of radioac- 
tivity after 6-['*F]fliuoroDOPA injection and its relationship 
to nerve terminal densities continue to be debated (Gjedde 
et al., 1991; Leenders, 1991; McGeer et al., 1992), and re- 
cent evidence suggests that DOPA decarboxylase, the en- 
zyme responsible for the first irreversible step in accumula- 
tion of radioactivity, is subject to regulation after acute or 
chronic manipulations of the dopaminergic system (Hadji- 
constantinou et al., 1992; Zhu et al., 1992). Although many 
of the radioligands for DA transporters have been used for 
successful in vivo imaging of dopaminergic terminals in the 
basal ganglia of hurnan brain, recent studies in animals have 
suggested that the numbers of neuronal membrane trans- 
porters might be regulated by changes in endogenous DA 
levels (Scheffel et al., 1991; Kilbourn et al., 1992), or 
chronic drug administration (Wiener et al., 1989; Ikegami 
and Prasad, 1990; Sharpe et al., 199 1). For use as a quantita- 
tive measure of neuironal densities, a process or binding site 
that does not undergo such regulation would be preferable, 
and thus alternatives to the neuronal membrane transport- 
ers might be investigated. 
A second specific marker for monoaminergic nerve termi- 
nals is the transporler site located on membranes of presyn- 
aptic vesicles, which is responsible for movement of mono- 
amines from the cytosol to the lumen of the vesicle (Henry 
and Scherman, 1989). Three ligands-reserpine, ketan- 
serin, and tetrabenazine (TBZ)-are high-affinity inhibitors 
of this transporter, although none of these ligands distin- 
guishes among the different monoaminergic neurons (DA, 
noradrenaline, or serotonin). Radioligand binding assays 
for the vesicular transporter have been developed using [3H]- 
reserpine and [3H]dihydrotetrabenazine ([3H]TBZOH), and 
autoradiographic studies have reported using [3H]reserpine, 
[3H]TBZOH, and 7-amin0-8-['~~I]iodoketanserin (for re- 
view, see Henry anid Scherman, 1989). Binding of such ra- 
dioligands in the striatum is due predominantly to dopami- 
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nergic terminals, and excellent correlations between reduc- 
tions in [3H]TBZOH binding and dopaminergic terminal 
loss (measured by tyrosine hydroxylase activity) have been 
demonstrated following stereotactic brain lesions in ani- 
mals (Masuo et al., 1990) or in autopsy samples from Par- 
kinson's disease patients (Scherman et al., 1989). We have 
recently prepared TBZ in a high-specific-activity, carbon- 1 1 
(@+, = 20.4 min)-labeled form (DaSilvaet al., 1993), and 
we describe here the initial in vivo human imaging of vesicu- 
lar monoamine transporters using this new radioligand. 
EXPERIMENTAL PROCEDURES 
Human subjects 
Two 26-year-old healthy volunteers participated in this 
study. There were free of significant medical, neurologic, 
and psychiatric illness, and they were nonsmokers receiving 
no centrally acting medications. The studies were approved 
by the University of Michigan Institutional Review Board, 
and written informed consent was obtained for both studies. 
PET imaging and experimental design 
A cutaneous vein was cannulated for injection of the ra- 
dioisotope, and the subjects were positioned supine in the 
gantry of a CTI/Siemens model 93 1/08- 15 tomograph. This 
scanner simultaneously acquires 15 contiguous slices over 
an - 10-cm axial field of view, with a reconstructed in-plane 
spatiai resolution of 7-8 mm. ["CITBZ (27.5 or 27.6 mCi; 
specific activities, > 1,000 Ci/mmol) in a volume of 3-4 ml 
was injected as a bolus. A dynamic series of PET scans was 
obtained over a 60-min period, beginning with frames of 
short duration (30 s) and progressing to 10-min frames at 
the end of the imaging period. 
Realignment of images 
Reconstructed images were realigned using radioactive 
scalp fudiciary beads to correct for subject motion during 
the scan session. Beads were labeled with 5-10 pCi of "C 
and securely taped to positions on the forehead and behind 
and above each ear. All image frames obtained were then 
reoriented to a single frame acquired at 5-7.5 min. This 
method allows for correction of three translational and 
three rotational degrees of freedom to within ~ 0 . 5  mm and 
1 O,  respectively. 
Data analysis 
Regions of interest for striatum, thalamus, cortex, and 
cerebellum were determined on the early images (summa- 
tion of images from 3 to 5 rnin), which most reflect initial 
radiotracer distribution. These regions of interest were then 
mapped to the entire temporal image sequence to determine 
the time-dependent concentration of radiotracer in differ- 
ent brain regions. 
RESULTS AND DISCUSSION 
Of the three high-affinity ligands for the vesicular mono- 
amine transporter, ketanserin, reserpine, and TBZ, we have 
chosen to study TBZ because of its low toxicity, rapid and 
short-lived pharmacological actions, and ease of radiolabel- 
ing. It is a well-characterized drug that has been used clini- 
cally for more than 2 decades (Pletscher et al., 1962). 
["CITBZ, labeled with the short half-life positron-emitter 
radionuclide carbon- 1 1, was injected into two normal hu- 
man subjects, and the brain distribution of the radiochemi- 
cal was imaged for 60 min. Representative images at 1-3 
rnin and from 20 to 60 rnin are shown in Fig. I .  Brain 
uptake (estimated from count rates in early frames of the 
study) of radioligand was high, similar to that observed 
with [LIC]flumazenil (Koeppe et al., 1991) and ["C]- 
tropanylbenzilate (Frey et al., 1990), radioligands that 
readily cross the blood-brain barrier. As shown in Fig. 2, 
egress of radioactivity from brain regions was very rapid, 
with the best differentiation of basal ganglia from cortex 
visible at 20-30 min after injection. Longer retention of the 
radioligand in the basal ganglia is most likely due to binding 
to the higher numbers of monoaminergic nerve terminals in 
these regions (Henry and Scherman, 1989). Although we 
have not performed blocking studies in humans to assign 
this binding definitively to the vesicular transport site, stud- 
ies in mice (DaSilva and Kilbourn, 1992) and monkeys (Da- 
Silva et al., 1992) have shown that striatal retention of this 
radiotracer can be blocked with reserpine, TBZ, and ketan- 
senn but not inhibitors of neuronal DA transport (GBR 
12909) or DA D, receptors (haloperidol). PET studies of 
["CITBZ in a unilateral MPTP-lesioned monkey have 
clearly demonstrated that at tracer doses there is only a pre- 
synaptic localization for this radioligand (DaSilva et al., 
This work represents the first in vivo PET imaging of a 
1993). 
human vesicular neurotransmitter 
["CITBZ appears very suitable for 
transporter. Although 
qualitative imaging of 
FIG. 1. Representative images of human brain distribution of 
["CITBZ at 1-3 min (A) and 20-60 min (B) following intravenous 
injection. Shown are three of the 15 simultaneously acquired 
transaxial slices, which represent planes 8.4 (left), 5.7 (center), 
and 3.0 (right) cm above and parallel to the canthomeatal line. 
These planes pass through the levels of the cingulate cortex; 
caudate nucleus, putamen and inferior thalamus; and cerebellum, 
pons, and inferior frontal and temporal lobes, respectively. Distri- 
bution at early times (A) resembles that obtained with blood flow 
agents. Higher residual radioactivity levels are clearly seen in the 
basal ganglia by 20 rnin postinjection (B, center), consistent with 
greater retention of ["CITBZ in this region of highest monoamin- 
ergic innervation. Images in B have been scaled up by a factor of 
3 to allow comparison with the early images in A; absolute radioac- 
tivity levels are significantly lower in the later images (see Fig. 2). 
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2.5 I I 
-i 2.0 
L- 2 1.5 
N" 1.0 
B - 0.5 u m - zu 0.0 
0 15 30 45 60 
time post-injection, min 
Tissue time-activitv curves following intravenous iniec- 
tion of [''CITBZ. Regional brain levels in striaturn (A). thalamus 
(O), cerebellum (O), and cortex (A) were determined using region 
of interest analysis of PET images. Time points shown are the 
midpoints of the acquired images. 
vesicular transporters and may have application in PET 
studies of dopaminergic terminal losses in various neurode- 
generative diseases, it is not likely to be the radioligand of 
choice for quantitative in vivo PET imaging because of the 
possible formation of a radiolabeled metabolite [ "C]- 
TBZOH, formed by reduction of ["CITBZ in vivo. This 
metabolite shows nearly identical in vitro binding affinity 
for the monoamine vesicular transporter (Henry and Scher- 
man, 1989), and thus it is possible that the images obtained 
here represent the combined localizations of ["CITBZ and 
the metabolite ["CITBZOH. Existence ofa radiolabeled me- 
tabolite, particularly one with similar pharmacological prop- 
erties but perhaps different physiochemical properties, 
would complicate pharmacokinetic modeling of the in vivo 
data. Our work does demonstrate, however, that in vivo 
imaging studies of the monoaminergic vesicular uptake sys- 
tem are feasible, and qualitative studies of loss of this site in 
neurodegenerative disorders might immediately be under- 
taken. With development of an improved radioligand that 
does not form radiolabeled metabolites, this presynaptic site 
might serve as a quantitative measure of dopaminergic ter- 
minals. In addition, the possible physiological regulation of 
vesicular transporters by either endogenous DA or chronic 
dopaminergic drugs is unknown at this time and will need 
to be examined. 
These in vivo PET results also confirm the interactions of 
[''CITBZ with multiple monoamine systems, as uptake and 
retention of radioligand are evident in the thalamus (nor- 
adrenaline) and cerebellum (noradrenaline and serotonin), 
although pharmacokinetic modeling of radiotracer distribu- 
tion will be necessary to characterize fully ["CITBZ distri- 
bution in these tissues. In rodents the in vivo retention of 
["CITBZ in various brain regions correlates very well 
( r 2  = 0.96; data not shown) with in vitro binding of [3H]- 
TBZOH (Henry and Scherman, 1989), and this specific 
binding in all tissues can be blocked with pharmacological 
doses of unlabeled TBZ or reserpine. Vesicular transporters 
for monoamines have only recently been cloned and se- 
quenced (Liu et al., 1992); although they can be considered 
as members of the 12 membrane-domain transporter super- 
family (Uhl, 1992), they are not homologouswith the neuro- 
nal monoamine transporters, which do show monoamine 
selectivities (Giros et al., 1992). An intriguing possibility is 
the potential existence of multiple subtypes of vesicular 
transporters, exhibiting unique monoamine specificities. 
In conclusion, we have demonstrated for the first time in 
vivo imaging of the vesicular monoamine transport system 
in human brain. In combination with development of ra- 
dioligands for the specific vesicular transporter for acetyl- 
choline (Jung et al., 1990; Kilbourn et al., 1990; Widen et 
al., 1992), including successful single photon emission com- 
puted tomographic imaging in humans (D. E. Kuhl et al., 
unpublished data), it may soon be possible routinely to 
image and quantify these important, specific neuronal popu- 
lations in the living human brain. 
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